Selecta Biosciences, Inc.
http://www.selectabio.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Selecta Biosciences, Inc.
Controversial Ginkgo Will Team With Persephone On Bacterial Delivery Of Microbial Therapies
Deal Snapshot: In its third biopharma collaboration this year, Ginkgo will apply its genetic engineering technologies to using Bacteroides for stable delivery of microbiome medicines.
Takeda Teams With Evozyne On Protein Design For Gene Therapy
Deal Snapshot: Building on a 2021 tie-up between Takeda and the Paragon start-up, Evozyne will seek novel protein sequences for inclusion in gene therapies for rare disease indications.
Asia Deal Watch: Huadong Licenses Two Cancer ADCs From Heidelberg Pharma
German firm’s antibody-drug conjugates use amanitin payload. Plus deals involving Sanwa Kagaku/Crinetics, Takeda/Code Bio, Taro/Alchemee, Mankind/Dr. Reddy’s and more.
Big Pharma’s Busiest Deal-Makers In 2021 Were Less Prolific Than In 2020
Totals for aggregate deals and in the M&A, alliance and divestment categories were similar among the 10 busiest deal makers from 2020 to 2021, but COVID-19 may have driven a more hectic deal-making pace overall in 2020.
Company Information
- Industry
-
Pharmaceuticals
- Vaccines
-
Biotechnology
- Gene Therapy, Cell Therapy
- Large Molecule
- Nanotechnology, Chips, etc.